Relay Therapeutics Announces Initial Clinical Data Demonstrating that RLY-2608 Selectively Targets Multiple PI3Kα Mutations
Multiple doses achieved sustained target exposure of ~80%+ mutant PI3Kα inhibition No Grade 3 hyperglycemia, rash or diarrhea observed at target exposures Favorable initial safety profile at... | April 18, 2023
United States Caroline Glen Don Bergstrom Exchange Commission Relay Therapeutics Inc American Association For Cancer Research
Source: marketscreener.com